Back

Cardiovascular Efficacy of Evolocumab in Patients with Obesity: Updates from FOURIER Trial

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Smaller trials, trial updates, and other studies on lipid therapy Drug therapy ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Yu Mi Kang

Harvard Medical School Teaching Hospital, Boston (United States of America)

4 More presentations in this session

Presentation thumbnail
Apolipoprotein A-I infusions and cardiovascular outcomes in patients with acute myocardial infarction and hyperlipidemia
Doctor C. Gibson (Boston, US)
Slides Video
Presentation thumbnail
Alternative LDL cholesterol lowering strategy vs. high-intensity statin strategy: An individual patient data meta-analysis from the randomized RACING and LODESTAR trials
Professor M. Hong (Seoul, KR)
Slides Video
Presentation thumbnail
A randomised, placebo-controlled phase 3 study of plozasiran in patients with familial chylomicronemia syndrome
Professor G. Watts (Perth, AU)
Slides Video
Presentation thumbnail
ApoA-I Infusions and Burden of Ischemic Events after Acute Myocardial Infarction
Doctor G. Chi (Boston, US)
Slides Video

Access the full session

Session thumbnail
Smaller trials, trial updates, and other studies on lipid therapy
Video

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
Lipid control in cardiovascular patients
thumbnail
Congress Presentation
Fix the plaque, fight the lipids: why low-density lipoproteins still matter after percutaneous coronary intervention
thumbnail
Congress Presentation
What’s new in LDL lowering?

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources